Barriers to the conduct of randomised clinical trials within all disease areas

Snezana Djurisic*, Ana Rath, Sabrina Gaber, Silvio Garattini, Vittorio Bertele, Sandra Nadia Ngwabyt, Virginie Hivert, Edmund A.M. Neugebauer, Martine Laville, Michael Hiesmayr, Jacques Demotes-Mainard, Christine Kubiak, Janus C. Jakobsen, Christian Gluud

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Abstract

Background: Randomised clinical trials are key to advancing medical knowledge and to enhancing patient care, but major barriers to their conduct exist. The present paper presents some of these barriers. Methods: We performed systematic literature searches and internal European Clinical Research Infrastructure Network (ECRIN) communications during face-to-face meetings and telephone conferences from 2013 to 2017 within the context of the ECRIN Integrating Activity (ECRIN-IA) project. Results: The following barriers to randomised clinical trials were identified: inadequate knowledge of clinical research and trial methodology; lack of funding; excessive monitoring; restrictive privacy law and lack of transparency; complex regulatory requirements; and inadequate infrastructures. There is a need for more pragmatic randomised clinical trials conducted with low risks of systematic and random errors, and multinational cooperation is essential. Conclusions: The present paper presents major barriers to randomised clinical trials. It also underlines the value of using a pan-European-distributed infrastructure to help investigators overcome barriers for multi-country trials in any disease area.

OriginalsprogEngelsk
Artikelnummer360
TidsskriftTrials
Vol/bind18
Udgave nummer1
DOI
StatusUdgivet - 1 aug. 2017

Fingeraftryk

Udforsk hvilke forskningsemner 'Barriers to the conduct of randomised clinical trials within all disease areas' indeholder.

Citationsformater